ZZM-1220

Overview

ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC 50 s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-156285
• CAS No.: 3053365-82-2
• Molecular Formula: C25H29N5O3
• Molecular Weight: 447.53
• Purity: 98.74%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (5.59 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source